Business Wire

Zeitview Acquires Heliolytics, Becoming the Market Leader in Solar Aerial Inspections

6.9.2023 13:00:00 EEST | Business Wire | Press release

Share

Zeitview today takes the lead in advanced aerial inspections for energy and infrastructure by acquiring Heliolytics, which specializes in photovoltaic (PV) system performance via aerial inspection and integrated analytics. The acquisition of this former division of NovaSource Power Services enables the combining of Heliolytics' data insights with Zeitview’s expertise in aerial inspection technologies. The majority of Heliolytics staff will join Zeitview, and the team’s presence in Toronto, Canada, will continue. The amount of the deal was not disclosed.

"Heliolytics are pioneers in the solar industry and have earned a commendable reputation for their unwavering commitment to quality, precision, and exceptional customer service—values we hold in the highest esteem,” said Dan Burton, founder and Chief Executive Officer at Zeitview. “Their expertise and dedication are valuable as we continue developing groundbreaking solutions that redefine inspection standards within the renewable energy sector. We are excited for this next chapter in our journey, where our united teams create a complete market-winning solution."

For renewable energy customers, this collaboration reinforces Zeitview's multi-asset approach to solar, wind, and utilities. For property owners, it offers critical insights into the performance of their rooftop solar facilities. For all customers, Heliolytics' international operations in Europe, Latin America, and the Asian Pacific are also being combined with Zeitview's global footprint in those same regions.

“Joining forces with Zeitview is a tremendous opportunity to further the renewable energy industry,” said Jocelyne Moyer, Head of Heliolytics. Post-acquisition, Moyer takes the title of Senior Director of Strategy and Operations at Zeitview. “We have a shared commitment with Zeitview to deep client partnerships, science-driven innovation, and unparalleled responsiveness to our global clients. I am excited to join the leadership team and look forward to collaborations that will strengthen Zeitview’s role in the operations and maintenance of renewable energy assets.”

Heliolytics' inspection tools and integrated analytics are now supported by Zeitview's AI/ML data processing engine. With this addition, Zeitview doubles the reach and breadth of its airplane operations and adds topography, EPC, and drone solutions to Heliolytics, all of which can translate into faster, more comprehensive customer results.

With the sale of Heliolytics to Zeitview, NovaSource Power Services continues to offer best-in-class aerial inspection software and services to their customers via Zeitview.

“We are thrilled to continue our longstanding partnership with the Heliolytics team under the Zeitview name,” said Timo Moeller, Chief Growth Officer, NovaSource Power Services. “Zeitview’s impressive inspection and software tools will enhance the insights we currently use to support operations and maintenance requests. It is clear that the Zeitview team deeply understands our data needs and is committed to providing continued unrivaled expertise as aerial inspection providers to support our growth.”

A complete integration of Heliolytics operations, data capture, and software into Zeitview’s market-leading global solar solution is expected to be finished by the end of 2024.

To learn more about how Zeitview supports global energy and infrastructure through advanced inspections and actionable data, visit www.zeitview.com.

ABOUT ZEITVIEW

As a single partner for aerial inspections across a broad spectrum of industries, including solar, wind, real estate, telecom, and utility assets, Zeitview is trusted by the largest enterprises worldwide to deliver fast, accurate insights that optimize asset performance and reduce operating and maintenance costs. Combining state-of-the-art aerial inspection software with the ability to capture in-depth visual data via airplanes and drones, Zeitview harnesses the power of artificial intelligence and machine learning. Such aerial intelligence delivers customers actionable insights in near real-time and empowers organizations to make better-informed decisions about their most critical assets at scale.

Learn more about Zeitview's cutting-edge solutions at www.zeitview.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Technica Communications for Zeitview
Cait Caviness
zeitview@technica.inc

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye